21 Feb 2025
As the COVID-19 pandemic has ended, the global focus has shifted from "pandemic response" to "long-term management". With no ongoing nationwide serosurveillance studies, our understanding of the level of immunity in the general population has diminished. In this study, we screened random samples from a biorepository serving the largest health board in Scotland for antibodies against SARS-CoV-2 to define the current immunological landscape, informing vaccine strategies going forward.
Useful Resources
Related Articles
-
Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant
BY Julia Stowe et al. -
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
BY Chang Liu et al. -
Depression, Anxiety, and Lifestyle Among Essential Workers: A Web Survey From Brazil and Spain During the COVID-19 Pandemic
BY Raquel Brandini De Boni, et al. -
A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein
BY Qu et al. -
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
BY Thiago Cerqueira-Silva et al.
Please Sign in (or Register) to view further.